Posted by Michael Wonder on 23 Sep 2022
1,500 people set to receive new skin cancer treatment that reduces the risk of it returning and spreading
23 September 2022 - Around 1,500 people aged 12 years and over with melanoma are set to benefit from pembrolizumab (also called Keytruda and made by MSD), a drug that reduces the chance of it returning, following final draft NICE guidance published today.
Pembrolizumab is the first treatment recommended by NICE for this stage of melanoma (2B and 2C) following surgery to remove the tumours (called an adjuvant treatment).
